Strengthening Regional and Global Aspirations
Venus Remedies Limited, a leading Indian exporter of generic drugs, has received marketing authorization from Indonesia, Southeast Asia’s largest pharmaceutical market, for its Enoxaparin in pre-filled syringes across all major strengths. This approval strengthens the company’s presence in Indonesia. It also supports its broader expansion strategy in Southeast Asia.
Addressing Indonesia’s Growing Cardiovascular Disease Burden
“Indonesia has the highest burden of cardiovascular diseases in the region due to an aging population and lifestyle changes. “Our Enoxaparin will provide a cost-effective solution to manage clot-related conditions,” said Mr. Saransh Chaudhary, President, Global Critical Care, Venus Remedies. He is also the CEO of Venus Medicine Research Centre.
Enoxaparin: A Critical Anticoagulant
As per the press release, Enoxaparin is a key anticoagulant. It plays a vital role in preventing and treating blood clots. This helps reduce the risk of deep vein thrombosis and pulmonary embolism. The global Enoxaparin market, valued at USD 3.3 billion in 2023, is expected to reach USD 5.4 billion by 2032, growing at a CAGR of 7.1%–7.9%. Venus Remedies produces over 10 million units annually at its autonomous robotic facility, positioning itself to secure a significant market share in Southeast Asia and beyond.
Growing Anticoagulant Market in Southeast Asia
The Southeast Asian anticoagulant market is projected to reach USD 550.7 million by 2029, growing at a CAGR of 7.84%. Indonesia’s market alone is set to expand at a CAGR of 7.72%, reaching USD 140.3 million by 2029. This growth presents a substantial opportunity for Venus Remedies to further establish itself as a key player in the region.
India’s Strong Trade Ties with Indonesia
“India’s pharmaceutical exports to Indonesia were valued at USD 84.53 million in 2023, highlighting strong trade relations between the two nations,” said Mrs. Aditi Chaudhary, President, International Business, Venus Remedies. “While anticoagulants remain a key focus, we are also expanding into other therapeutic areas. Our goal is to meet critical medical needs and enhance patient outcomes with affordable generic drugs.”
Expanding Global Footprint
With over a dozen global marketing authorizations for Enoxaparin, Venus Remedies continues to expand its international presence. This milestone reinforces the company’s commitment to providing accessible and high-quality healthcare solutions worldwide.